Chronic Heart Failure
Chronic heart failure (CHF) occurs when the heart muscle is permanently weakened or stiffened and can no longer pump blood with enough force to supply the body’s organs. It is a progressive condition managed rather than cured, and it affects tens of millions of people across Asia, with particularly high rates in South Asia and South-East Asia linked to hypertension, type 2 diabetes, and rheumatic heart disease.
Medicines used to treat Chronic Heart Failure
Candesartan Tablets
4 · 8 · 16mg
Indicated to manage hypertension, this treatment is developed to alleviate cardiac strain and effectively support patients in reaching target blood pressure levels.
What drives the condition forward
Heart failure is almost always the downstream result of another problem. Longstanding high blood pressure, coronary artery disease, and uncontrolled diabetes are the most common upstream causes in the region. As the heart compensates, it remodels, enlarging or thickening, and this remodelling itself worsens function over time. Fluid builds up in the lungs and lower limbs because the kidneys respond to poor circulation by retaining salt and water.
Symptoms worth watching
Breathlessness on exertion (and eventually at rest), ankle and leg swelling, and persistent fatigue are the hallmark complaints. A dry cough, especially when lying flat, and rapid or irregular heartbeat are also common. Symptoms tend to worsen gradually, but a sudden sharp deterioration, new breathlessness at rest, coughing up frothy or pink sputum, or chest pain, needs urgent medical attention the same day.
How heart failure is managed today
Treatment targets the neurohormonal pathways that accelerate the disease. Beta-blockers such as carvedilol and bisoprolol slow the heart and reduce harmful adrenaline signalling. Angiotensin-receptor blockers like candesartan or valsartan lower blood pressure and ease the heart’s workload. The combination drug sacubitril (paired with valsartan) goes further by also blocking natriuretic peptide breakdown, which has meaningfully reduced hospital admissions in trials.
More recently, dapagliflozin, originally developed for type 2 diabetes, has demonstrated clear survival benefit in heart failure regardless of whether a patient has diabetes, and is now a guideline-recommended option. Alongside medicines, a low-salt diet, daily weight monitoring, and graduated physical activity form the backbone of self-care for most people with CHF. See the heart and blood pressure category for the full range of medicines used in this condition.